AOD-9604 in Periam — Fat Loss Peptide Research Guide
AOD-9604 research guide for Periam. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
For anyone in Periam looking to source AOD-9604, the first thing to know is that this compound is distributed via specialist online vendors. The practical advantage of this online-only market is that serious vendors differentiate entirely through their analytical documentation, giving researchers access to better quality signals than any local market ever offers. A legitimate AOD-9604 supplier's COA should include HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all corresponding to the vial you receive. This guide gives Periam researchers the methodology to verify sourcing options methodically and source research-grade AOD-9604 with confidence.
AOD-9604: What the Research Shows
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Periam comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Evaluate AOD-9604 Vendors
Quality AOD-9604 sourcing begins with a useful first test: does this vendor publish batch-specific COAs proactively? Those who make this data freely available are operating transparently. When reviewing a AOD-9604 COA, verify: the batch number traces to your order, HPLC purity is ≥98%, mass spec establishes identity, and endotoxin levels are within acceptable research limits. Red flags in AOD-9604 vendor evaluation: prices far under typical market pricing, unclear production details, no community presence, and COAs that lack endotoxin data. Price is an unreliable primary filter for AOD-9604 quality — research-grade synthesis and testing has real costs that do not compress without quality compromise, so the lowest-priced options almost always involve trade-offs.
Order AOD-9604 — ships to Periam
COA-verified · International tracking · Research grade
Research compound status for AOD-9604 means risk characterisation relies on animal studies, in-vitro work, and limited human observations — rather than the large-scale clinical data that informs approved drug safety. Reconstitute AOD-9604 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg in 2mL gives a 2.5mg/mL solution — providing 25mcg per unit measured on a 100-unit syringe. Bacterial endotoxin contamination is the greatest safety hazard associated with research-grade peptides — verify endotoxin testing is present in the lot-matched certificate before any injectable research application. PubMed and related preprint servers provide the most complete literature coverage for AOD-9604 research; favour indexed journal publications over preprints over unreviewed preprints or forum reports.
Frequently Asked Questions
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
